Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome

References

• Frank S. Polycystic ovary syndrome. N Engl J Med 1995;333:853–61.
   PubMedGoogle Scholar
• Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998;338:1876–80.
   PubMed Web of Science ®Google Scholar
• Dunaif A, Segal K, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165–74.
   PubMed Web of Science ®Google Scholar
• Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774–800.
   PubMed Web of Science ®Google Scholar
• Ehrman DA, Barnes RB, Rosenfield RL,, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women polycystic ovary syndrome. Diabetes Care 1999;22:141–6.
   Google Scholar
• Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association. Endocr Rev 2003;24:302–12.
   PubMed Web of Science ®Google Scholar
• Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Chin Endocrinol (Oxf) 2000;52:595–600.
   PubMed Web of Science ®Google Scholar
• Fonseca V, Guba SC, Fink LM. Hyperhomocysteinemia and the endocrine system: implications for atherosclerosis and thrombosis. Endocr Rev 1999;20:738–59.
   Google Scholar
• Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998;338:1042–50.
   PubMed Web of Science ®Google Scholar
• Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991;324:1149–55.
   Google Scholar
• Schnyder G, Roffi M, Pin R, Flammer Y, Lange H, Eberli FR, Meier B, Turi ZG, Hess OM. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001;345:1593–600.
   Google Scholar
• Guzick DS. Cardiovascular risk in women with polycystic ovarian syndrome. Semin Reprod Endocrinol 1996;14:45–9.
   PubMedGoogle Scholar
• Birdsall MA, Farquar CM, White HD. Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann Intern Med 1997;126:32–5.
   Google Scholar
• Talbott E, Clerici A, Berga SL, Kuller L, Guzick D, Detre K, Daniels T, Engberg RA. Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J Clin Epidemiol 1998;51:415–22.
   PubMed Web of Science ®Google Scholar
• Yarali H, Yildirir A, Aybar F, Kabakci G, Bukulmez O, Akgul E, Oto A. Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome. Fertil Steril 2001;76:511–16.
   Google Scholar
• Vrbikova J, Bicikova M, Tallova J, Hill M, Starka L. Homocysteine and steroid levels in metformin-treated women with polycystic ovary syndrome. Exp Chin Endocrinol Dia-betes 2002;110:74–7.
   Google Scholar
• Randeva HS, Lewandowski KC, Drzewoski J, Brooke-Wavell K, O'Callaghan C, Czupryniak L, Hillhouse WE, Prelevic MG. Exercise decreases plasma total homocysteine in over-weight young women with polycystic ovary syndrome J Chin Endocrinol Metab 2002;87:4496–501.
   Google Scholar
• Loverro G, Lorusso F, Mei L, Depalo R, Cormio G, Selvaggi L. The plasma homocysteine levels are increased in polycystic ovary syndrome. Gynecol Obstet Invest 2002;53:157–62.
   PubMed Web of Science ®Google Scholar
• Wijeyaratne CN, Nirantharakumar K, Balen AH, Barth JH, Sheriff R, Belchetz PE. Plasma homocysteine in polycystic ovary syndrome: does it correlate with insulin resistance and ethnicity? Chin Endocrinol (Oxf) 2004;60:560–7.
   PubMed Web of Science ®Google Scholar
• Schachter M, Raziel A, Friedler S, Strassburger D, Bern O, Ron-El R. Insulin resistance in patients with polycystic ovary syndrome is associated with elevated plasma homocysteine. Hum Reprod 2003;18:721–7.
   Google Scholar
• Wild RA, Painter RD, Coulson PB, Carruth KB, Ramey RB. Lipoprotein lipid concentrations as cardiovascular risk in patients with polycystic ovary syndrome. J Chin Endocrinol Metab 1985;61:946–50.
   Google Scholar
• Homburg R. What is polycystic ovarian syndrome? Hum Reprod 2003;17:2495–9.
   Web of Science ®Google Scholar
• Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Chin Endocrinol Metab 1961;21:1440–7.
   PubMed Web of Science ®Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and )3-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–19.
   PubMed Web of Science ®Google Scholar
• De Leo V, Marca A, Petraglia F. Insulin lowering agents in the management of polycystic ovary syndrome. Endocr Rev 2003;24:633–67.
   Google Scholar
• Orio F, Palomba S, Di Biase S, Calao A, Tauchmanova L, Savastano S, Labella D, Russo T, Zullo F, Lombardi G. Homocysteine levels and C677T polymorphism of methyle-netetrahydrofolate reductase in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:673–9.
   PubMed Web of Science ®Google Scholar
• Boulman N, Levy Y, Leiba R, Shachar S, Linn R, Zinder O, Blumenfeld Z. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Chin Endocrinol Metab 2004;89:2160–5.
   Google Scholar
• Sills ES, Genton MG, Perloe M, Schattman GL, Bralley JA, Tucker MJ. Plasma homocysteine, fasting insulin, and androgen patterns among women with polycystic ovaries and infertility. J Obstet Gynaecol Res 2001;27:163–8.
   PubMed Web of Science ®Google Scholar
• De Pergola G, Pannaciulli N, Zamboni M, Minenna A, Brocco G, Sciaraffa M, Bosello O, Giorgino R. Homocysteine plasma levels are independently associated with insulin resistance in normal weight, overweight and obese pre-menopausal women. Diabetes Nutr Metab 2001;14:253–8.
   PubMedGoogle Scholar
• Tallova J, Tomandl J, Bitokova M, Hill M. Changes of plasma total homocysteine levels during the menstrual cycle. Eur J Chin Invest 1999;129:1041–4.
   Google Scholar
• Brattstrom L, Lindgren A, Israelsson B, Andersson A, Hultberg B. Homocysteine and cysteine: determinants of plasma levels in middle-aged and elderly subjects. J Intern Med 1994;236:633–41.
   Google Scholar
• Guttormsen AB, Schneede J, Fiskerstrand T, Ueland PM, Refsum HM. Plasma concentrations homocysteine and other aminothiol compounds are related to food intake in healthy human subjects. J Nutr 1994;124:1934–41.
   Google Scholar
• Glueck CJ, Shaw P, Lang JE, Tracy T, Sieve-Smith L, Wang,. Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients. Am J Cardiol 1995;75:132–6.
   Google Scholar
• Tonstad S, Refsum H, Ueland PM. Association between plasma total homocysteine and parental history of cardiovas-cular disease in children with familial hypercholesterolemia. Circulation 1997;96:1803–8.
   Google Scholar
• Ajabnoor MA, Al-Ama MN, Banjar Z, Rafee AA, Sheweita SA. Homocysteine level and other biochemical parameters in cardiovascular disease patients with diabetes mellitus. Med Sci Monit 2003;9:523–7.
   Google Scholar
• Soysal D, Savas S, Susam I, Cevik C, Goldeli E, Sozmen E, Guneri S. The association of plasma homocysteine, coronary risk factors and serum nitrite in patients with coronary artery disease, vascular syndrome X and healthy subjects. Anadolu Kardiyol Derg 2003;3:26–36.
   Google Scholar
• Buccianti G, Baragetti I, Bamonti F, Furiani S, Dorighet V, Patrosso C. Plasma homocysteine levels and cardiovascular mortality in patients with end-stage renal disease. J Nephrol 2004;17:405–10.
   PubMedGoogle Scholar